17 results
10-K
2023 FY
EX-10.22
NMRA
Neumora Therapeutics Inc.
7 Mar 24
Annual report
4:05pm
in their individual capacities. Except as may be prohibited by applicable law, the foregoing waiver includes the ability to assert claims as a plaintiff
10-K
2023 FY
NMRA
Neumora Therapeutics Inc.
7 Mar 24
Annual report
4:05pm
, settlements, and damages awarded to plaintiff.
Table of Contents
ITEM 1B. Unresolved Staff Comments.
None.
ITEM 1C. Cybersecurity.
Management
10-K
2023 FY
EX-10.23
NMRA
Neumora Therapeutics Inc.
7 Mar 24
Annual report
4:05pm
waiver includes the ability to assert claims as a plaintiff or class member in any purported class or collective action or representative proceeding
S-1
EX-10.11
NMRA
Neumora Therapeutics Inc.
25 Aug 23
IPO registration
5:03pm
be prohibited by applicable law, the foregoing waiver includes the ability to assert claims as a plaintiff or class member in any purported class or collective
S-1
EX-10.15
d5lol243usortjg5t467
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.10
5jqyyo
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.16
12e3csteaku3w eqp2c
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.20
d3ddxer27ukiiy87oyn1
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.9
iovmf7 gcc9yxreyb
25 Aug 23
IPO registration
5:03pm
DRS/A
EX-10.21
6qzjes632j
9 Aug 23
Draft registration statement (amended)
12:00am
DRS/A
EX-10.10
s4h64a
30 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
EX-10.11
ulwvrh pus9
30 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
EX-10.12
ef8c1
30 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
EX-10.24
q9f20yeouu65s2vq8l
2 May 22
Draft registration statement (amended)
12:00am
DRS/A
EX-10.25
u5zlfrwujrk62oju
2 May 22
Draft registration statement (amended)
12:00am
DRS/A
EX-10.6
w21gbspk2x7qhfrywp
23 Dec 21
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next